INTRODUCTION 1
Members of the genus Candida, and in particular Candida albicans, are opportunistic 2 pathogens frequently isolated from the mucosal surfaces of immunocompetent individuals. In 3 patients with predisposing conditions, including immunodeficiencies, pregnancy, diabetes 4 mellitus, or those receiving broad-spectrum antibiotics, C. albicans may cause mucosal and 5 systemic infections, which are frequently treated with azole, polyene or echinocandin 6 antifungal agents. Although these antifungal agents are active against most Candida isolates, 7 emergence of resistance has become a serious concern (23). In the last years, considerable 8 interest has been attracted by the antifungal activity of some antibodies (15, 22, 24, 26) , but 9 further work is needed in the light that the development of the most promising among them (30; 10 Mycograb, Novartis) has recently been discontinued 11 (http://www.novartis.com/newsroom/media-releases/en/2010/1449020.shtml). 12
We developed a monoclonal antibody (mAb), designed C7, against a stress mannoprotein 13 of >200 kDa from the cell wall of C. albicans. This antibody reacted with a peptide epitope 14 present in Als3 as well as in a number of antigens from the blastoconidium and germ tube cell 15 was monitored by the system software, and the threshold cycle (CT) above the background for 1 each reaction was calculated. The CT value of 18S rRNA was subtracted from that of the gene 2 of interest to obtain the differential value (∆CT). The ∆CT of an arbitrary calibrator (e.g., 3 untreated sample) was subtracted from the ∆CT of each sample to obtain a ∆∆CT value. The 4 gene expression level relative to the calibrator was expressed as 2 -∆∆CT . 5
Candidacidal activity. The candidacidal activity of mAb C7 was assessed by a 6 modification of the method described previously (26). C. albicans cells grown overnight in an 7 orbital shaker in Sabouraud's broth at 22ºC and 120 rpm were collected and suspended in 8 sterile phosphate buffer saline pH 7.3 (PBS). At this point, 150 viable C. albicans cells 9 suspended in 100 µl of PBS were exposed to mAb C7 0.1 mg/ml. Parallel samples were run 10 with an irrelevant mouse monoclonal IgM (TEPC183, Sigma-Aldrich Química S.A., Madrid, 11 Spain). After 18 h of incubation at 37ºC, the fungal cells were collected and spread on 12
Sabouraud dextrose agar plates. The number of colony forming units (CFUs) was recorded 13 after 48 h of incubation at 37ºC. All values quoted represent mean figures derived from at least 14 three independent assays performed in triplicate. In order to reproduce the conditions used in 15 the microarray experiments, the candidacidal activity of mAb C7 was also assessed in Lee's 16 medium (42) supplemented with uridine (Sigma) at 0.1 g/l and amino acids (ornithine 0.0714 17 g/l, phenylalanine 0.5 g/l, threonine 0.5 g/l, proline 0.5 g/l and histidine 1 g/l; Sigma). All 18 values quoted represent mean figures derived from at least three independent assays performed 19 in triplicate. 20 C. albicans NCPF3153 cells incubated with mAb C7 were checked microscopically for 21 the presence or the absence of cell agglutination. MAbs 26G7 and 14-8 were used as controls 22 (8) . 23
Inhibition of metabolic activity. The inhibition of metabolic activity by mAb C7 was 24 studied by the 3-(4,5-dimethytiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction 25 on October 25, 2017 by guest http://aac.asm.org/ Downloaded from assay (27) . The MTT is a tetrazolium salt, which is reduced to a colored formazan product by 1 reducing enzymes present only in metabolically active living cells. Briefly, 10 7 cells of C. 2 albicans in 100 µl of PBS were incubated with 0.1 mg/ml of mAb C7 for 18 h at 37ºC in 3 enriched 5% CO 2 atmosphere, in 96-well microtiter plates (Greiner Bio-One GmbH, 4
Frickenhausen, Germany). After centrifugation at 600 xg for 8 min, the supernatants were 5 discarded and 100 µl of MTT (Sigma) dissolved in RPMI-PS at a concentration of 0.5 mg/ml 6 was added to each well. The plates were then incubated for 3 h at 37ºC in 5% CO 2 atmosphere, 7 and supernatants were discarded after centrifugation at 600 g for 8 min. One hundred 8 microliters of dimethyl sulfoxide (DMSO) (Sigma) was added to each well, and the formation 9 of the formazan product was measured at 490 nm in a Microplate Reader (Biotek ELx808, 10 Winooski, VT, USA). Each assay was performed in triplicate. 11
The LIVE/DEAD yeast viability kit (Molecular Probes, Eugene, Oreg.) was also used to 12 study the inhibition of metabolic activity by mAb C7 (0.1 mg/ml). The vital staining FUN-1, 13 which is processed by metabolically active yeast and results in a shift from green to red 14 fluorescence within vacuolar structures, was used as described elsewhere (25). FUN-1 stained 15 cells were observed under an epifluorescence microscope Eclipse 80i (Nikon, Tokyo, Japan) 16 with excitation wavelength of 435/82 and emission bands of 536/40 for green and red colors 17 respectively. The proportion of dead and alive cells was calculated by direct counting. 18
Influence of different iron sources on the candidacidal activity of mAb C7. C. 19 albicans strains were grown in an orbital shaker at 30ºC, 120 rpm, 18h, in YPD broth 20 supplemented with the iron chelator bathophenanthroline disulphonic acid disodium salt 21 (Sigma) 0.5 mM. Subsequently, the cultures were diluted 1:4 in the same medium and 22 reincubated for an additional period of 18 h for iron starvation. Cells were washed twice in PBS 23 and then used in the assay at a final concentration of 1.5x100.5 g/l, threonine 0.5 g/l, proline 0.5 g/l and histidine 1 g/l; Sigma). Ferritin (Type I; from horse 1 spleen, Sigma) was prepared as described elsewhere (1) and tested at a final concentration of 20 2 µg/ml. MAb C7 and an irrelevant IgM mAb (TEPC183, Sigma) were tested at a final 3 concentration of 0.1 mg/ml. After incubation at 30ºC in an orbital shaker (120 rpm) for 18 h, 4 the yeasts were plated onto YPD agar and CFU were counted after incubation at 30ºC for 48 h. 5
Results were expressed as percentage of growth inhibition compared to the respective control 6 treated with an irrelevant IgM. 7
In a series of experiments, C. albicans cells were grown overnight in Sabouraud broth at 8 22ºC in an orbital shaker at 120 rpm and then collected, washed twice in PBS and then 9 resuspended in sterile PBS pH 7.3. At this point, 150 viable C. albicans cells suspended in PBS 10 were exposed to mAb C7 at a concentration 0.1 mg/ml in combination with different 11 concentrations of iron (III) chloride hexahydrate (Merck, Darmstadt, Germany) or hemin 12 (Sigma). Parallel samples were run with an irrelevant mouse IgM mAb (TEPC183, Sigma). 13
Influence of ferrozine on C. albicans growth. For the assay, C. albicans NCPF 3153 14 was grown in YPD broth in an orbital shaker (120 rpm) at 30ºC for 18 h. Then, cells were 15 washed twice in PBS and used in the assay at a final concentration of 1.5x10 4 cells/ml in PBS 16 or in YPD broth, supplemented with 3-(2-Pyridyl)-5,6-diphenyl-1,2,4-triazine-4´,4´´-disulfonic 17 acid sodium salt (Ferrozine, Sigma) , at a final concentration of 10 mM when the assay was 18 performed in PBS or 100 mM when it was performed in YPD broth. 
RESULTS

1
Candidacidal and metabolic inhibitory activity of mAb C7. C. albicans NCPF 3153 2 does not multiply in PBS but cells remain viable, and the treatment with mAb C7 (0.1 mg/ml) 3 produced a 43.4% ± 1.47 reduction in the number of CFU compared to the control treated with 4 a commercial IgM. Beyond that, in Lee's medium, where C. albicans can grow, treatment with 5 mAb C7 produced a 98.97% ± 0.51 decrease in the CFU count (Table 3 ). In contrast to control 6 mAbs 26G7 and 14-8, which showed a strong agglutinating effect, mAb C7 did not agglutinate 7 the cells of C. albicans (data not shown), so the reduction in the number of CFU could not be 8 due to yeast cells agglutination mediated by the mAb C7. 9
This candidacidal effect of mAb C7 was also characterized by measuring the metabolic 10 activity of C. albicans through the MTT assay. As expected, incubation with mAb C7 (0.1 11 mg/ml) in PBS reduced the metabolic activity of C. albicans to 35.20% ± 3.77 compared to the 12 control with an irrelevant mAb (P=0.03). To further confirm this inhibitory effect, we used a 13 vital staining technique with the FUN-1 probe and registered that metabolically active cells 14 dropped to 31.4% ± 2.38 after incubation with mAb C7 (P= 0.016, Figure 1) . 15
Gene expression response to mAb C7 exposure. C. albicans SC5314 was grown in 16 modified Lee's medium (42) and diluted with fresh medium to reach an OD 600 of 0.1. The 17 diluted culture was split into two aliquots and mAb C7 was added to one of them. As the mAb 18 concentration 12.5 µg/ml was subinhibitory, we had to extend the incubation up to 18 h at 37ºC 19 in order to obtain enough sample to be processed. Candida morphology of both cultures was 20 mycelial. Two independent sets of RNA isolated from control and mAb C7-treated cells 21 respectively, were used to prepare two independent cDNA probe sets. A total of 50 genes were 22 found to be differentially expressed upon treatment with mAb C7. Of these, 29 were found to 23 be up-regulated and 21 down-regulated ( Candidacidal activity of mAb C7 on C. albicans mutants lacking key genes of the 13 iron acquisition systems. Since the expression data resembled those of an iron depletion 14 condition and it was very similar to the effect observed with the antifungal agent ciclopirox 15 olamine against C. albicans (28), we examined the effect of mAb C7 on several mutants 16 lacking key genes from iron uptake pathways. Most of the C. albicans mutants tested behaved 17 similarly to the control reference and parental strains (Table 3) . Only the mutant lacking TPK1 18 gene showed a significant reduction in the percentage of growth inhibition in the presence of 19 mAb C7. The tpk1∆/tpk1∆ mutant showed a 48.38% ± 8.03 inhibition of the growth and 20 tpk2∆/tpk2∆ a 91.88% ± 0.51.. Additionally, one mutant of C. albicans lacking ALS3 gene and 21
another heterozygous for ENO were also susceptible to the mAb C7 (Table 3) . 22
Influence of iron on the activity of mAb C7. To further investigate the relationship 23 between the candidacidal effect of mAb C7 and the iron acquisition in C. albicans, we 24 examined the effect of mAb C7 on fungal cells in the presence of different iron sources. Iron 25 (III) chloride reduced the inhibitory effect of mAb C7 on C. albicans NCPF3153, in a 1 concentration related manner, and concentrations ≥62.5 µM neutralized the growth inhibition 2 caused by the mAb (Figure 3 ). Similar results were observed using C. albicans SC5314 (data 3 not shown). The candidacidal activity of mAb C7 on C. albicans was also reduced by hemin, 4 its effect being more efficacious with increasing concentrations (>7.8 µM; Figure 3) ; 5 unfortunately, we were unable to run experiments with hemin concentrations >31.2 µM, due to 6 its reduced solubility. 7
Contrarily, ferritin (20 µg/ml) was not able to revert the candidacidal effect of mAb C7 on 8 C. albicans NCPF3153 growing in Lee's medium (98.91% ± 0.51 inhibition of growth in the 9 absence of ferritin, and 98.68% ± 0.91 with ferritin). Similar results were obtained with 10 SC5314 strain (95.92% ± 0.14 inhibition without ferritin, and 94.25% ± 1.16 with ferritin). 11
The growth of C. albicans in presence of the iron chelator ferrozine 100 mM was 12 inhibited to a similar extent to that produced by mAb C7 (99.86% ± 0.02 and 98.97% ± 0.51 of 13 control growth, respectively). 14 DISCUSSION 1
Results presented in this study confirm and extend our previous observation regarding the 2 candidacidal activity of mAb C7 (26), which seems to be independent of the growth conditions 3 since it is effective either on growing and resting cells. MAb C7 is not the only mAb described 4 as fungicidal. In this way K10, an antibody that mimics the activity of a Pichia anomala's 5 killer toxin shows a potent fungicidal effect on C. albicans (21, 26) . 6
The gene expression profiling of C. albicans revealed up-regulation of genes involved in 7 iron homeostasis as the main response to the treatment with mAb C7. Major changes included 8 the overexpression of genes CCC2, FET34, FTR1, FTR2, SIT1 and CTR1. CCC2 encodes a 9 copper transporting ATPase essential for inorganic iron assimilation pathways. FET34 is a 10 ferro-oxidase critical for Fe (II) uptake. FTR1 and FTR2 encode membrane iron transporters, 11
and SIT1 is a siderophore transporter involved in iron uptake. Up-regulation of all these genes 12 is consistent with low-iron concentration-induced changes in gene expression observed 13 previously in C. albicans (16). Furthermore, as copper is essential for Fe (II) uptake in C. 14 albicans, up-regulation of the high affinity copper transporter CTR1 also supports the 15 hypothesis of a mechanism of action for the mAb involving iron depletion. In this regard, we 16 also found that genes encoding cytochromes (CYB5, CYT1), and flavohemoglobin (YHB1), 17 broadly recognized as haem-and iron-containing proteins (5, 48) were down-regulated in 18 response to mAb C7. 19
In addition, we detected many enzyme genes down-regulated, including alcohol dehy-20 drogenases (CSH1, IFD6), phosphoenolpyruvate carboxykinase (PCK1), two members of 21 tricarboxilic acid (TCA) cycle, isocitrate dehydrogenase (IDP2) and succinate dehydrogenase 22 (SDH12),and superoxide dismutase (SOD5) which is a component of the cellular defence against 23 oxidative stress. Lan et al (18) reported that genes related to the TCA pathway were more highly 24 expressed at the high-iron condition; accordingly, our results would point to conditions with 25 on October 25, 2017 by guest http://aac.asm.org/ Downloaded from limited iron availability. Furthermore, iron depletion is known to alter cell-surface composition and 1 hydrophobicity of C. albicans (31, 41, 42) and we found four genes encoding GPI-anchored 2 proteins to be up-regulated in response to mAb C7. In particular RBT5 a protein from a family of 3 pathogenesis-related haem-binding proteins (44) 
C7. 12
The transcriptional response of C. albicans to mAb C7 suggests that the fungus is growing 13 under limited iron supply, and supports the theory that mAb C7 antifungal activity may be, at 14 least partially, caused by iron limitation. This response is similar to that registered for C. 15 albicans treated with ciclopirox olamine, an antifungal drug that acts as an iron chelator, 16 restricting the iron availability to the fungal cell and consequently inhibiting growth (20, 28) . In 17 our hands, the presence of the chelator ferrozine, reduced C. albicans growth extent in a 18 manner similar to that caused by mAb C7. 19 C. albicans can acquire iron from siderophores, hemoglobin and from a variety of ferric 20 iron chelates (16). The membrane transporter Sit1p allows C.albicans to use siderophores as iron 21 source (11). The acquisition of iron from hemoglobin is mediated by Rbt5p and Hmx1p (36, 22 43), whereas multiple genes are involved in the reductive uptake system that allows Fe(II) uptake 23 (17). Iron must first be reduced, then captured by a multicopper oxidase (7), and finally 24 internalized by a ferrous permease encoded by two highly homologous genes FTR1 and FTR2 1 (33). 2
One explanation for the mechanism of action of mAb C7 on C. albicans could be the 3 blockage of one of the iron acquisition systems. Since iron trace amounts in Lee's medium are 4 acquired by the reductive pathway, our first hypothesis was that mAb C7 would be blocking the 5 reductive uptake pathway. To test this hypothesis, we tried to neutralize the candidacidal effect 6 of mAb C7 by adding to the medium iron (III) chloride. Interestingly, high iron concentrations 7 reversed the effect of mAb C7 on C. albicans, suggesting that mAb C7 was blocking the 8 reductive pathway. Additional evidence for this hypothesis comes from the experiments with 9 hemin, which is taken up by a different uptake system. Addition of hemin to the culture 10 medium neutralized the candidacidal effect of mAb C7. In agreement with this hypothesis, 11 supplementation of the culture medium with ferritin, which is taken up by the reductive uptake 12 pathway, was not able to sort out the effect of mAb C7. 13
Taken together, there are several lines of evidence suggesting that the candidacidal effect 14 of mAb C7 is related to the blockage of the iron uptake by the reductive pathway. To obtain 15 further evidence to support this hypothesis, we tested a number of C. albicans mutants lacking 16 key genes of each of the three known iron acquisition systems. The action of mAb C7 on the 17 sit1∆/sit1∆, rbt5∆/rbt5∆, and ftr1∆/ftr1∆ mutants was similar to that of the C. albicans wild-18 type strains, suggesting that the proteins encoded by these genes were not recognized by mAb 19 C7, or had a location in the cell protected from the action of the mAb. Since Saccharomyces 20 cerevisiae mutants lacking TPK2 have permanently activated the siderophore and the reductive 21 iron uptake systems (35), we assayed the effect of mAb C7 on C. albicans TPK1 and TPK2 22 mutants. Both strains were less sensitive to the action of mAb C7 when compared with an 23 irrelevant IgM. This behavior could be expected if C. albicans tpk proteins would negatively 24 regulate genes involved in iron uptake, as described for S. cerevisiae. Alternatively, the 25 iron-dependent enzymes and a depletion of cell energy (28). Since mAb C7 binds to cell wall 5 components of C. albicans including Als3 and enolase (4, 26, 29) , it is likely that interaction of 6 mAb C7 with cell wall proteins involved in the reductive pathway for iron acquisition causes 7 the blockage of the pathway and explains the candidacidal activity of the mAb. Interestingly, it 8 has been recently reported that Als3 mediates iron acquisition from host ferritin by binding the 9 iron storage protein to C. albicans (1). In our study, none of the TR-CaENO1∆/eno1∆ and 10 als3∆/als3∆ mutants were resistant to the candidacidal effect of mAb C7. These results were 11 possibly related to the existence of a compensatory effect, since as mAb C7 recognizes both 12 enolase and Als3, in absence of one of these proteins mAb C7 could still react with the other. 13
Ibrahim et al. (13) evaluated the iron chelator deferasirox as a therapeutic adjuvant for 14 mucormycosis and they concluded that abrogation of iron acquisition by the agents of 15 mucormycosis was a promising therapeutic strategy to improve clinical outcomes (13, 34). Thus 16 far, the mAb C7 has shown a protective effect in a murine model of invasive candidiasis (37). In 17 a similar way to that put forward for deferasirox, if the candidacidal effect of mAb C7 is related 18 to the blockage of the iron uptake by the reductive pathway of C. albicans, we could expect a 19 potential therapeutic application of the mAb, in combination with current antifungals. 20
In conclusion, our data suggest that the candidacidal activity of mAb C7 is related to a 21 blockage of the reductive iron acquisition pathway of C. albicans that induces changes in the 22 iron metabolism resembling those found under iron-limiting conditions. Further work to 23 elucidate the therapeutic potential of mAb C7 is warranted. 24 
